Skip to content

Pilot study of cognitive-behavioral therapy for Japanese adolescents with depression and/or anxiety

Japanese version of the unified protocol for transdiagnostic treatment of emotional disorders in adolescents: A pilot study using a randomized multiple-baseline design - UP-A pilot study in Japan

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1030210215
Enrollment
12
Registered
2021-07-30
Start date
2021-08-06
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MDD, anxiety disorders, OCD, PTSD, adjustment disorders emotional disorders

Interventions

UP-A is individual cognitive-behavioral therapy (CBT) for adolescents comprising eight core modules (motivation enhancement, psychoeducation about emotions, behavioral activation, awareness of body se
cognitive behavioral therapy, unified protocol

Sponsors

Ito Masaya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adolescents who meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder, separation anxiety disorder, specific phobia, social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, or adjustment disorders. 2) Adolescents who have at least moderate or worse symptoms on the Clinical Global Impressions-Severity (CGI-S) scale at the time of inclusion (CGI-S >= 4). 3) Adolescents aged between 12 and 19 years at the time of inclusion. 4) Adolescents and their parents who understand the purpose and content of this study and voluntarily provide a written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1) Adolescents who meet the DSM-5 criteria for a hypomanic episode, manic episode, or any psychotic disorder at the time of inclusion. 2) Adolescents who have significant suicidality at the time of inclusion. 3) Adolescents who have received other structured psychotherapy at the time of inclusion or are planning to receive it during the intervention period. 4) In the case of adolescents using psychotropic medications, less than 8 weeks' use after dosage stabilization. 5) Adolescents with an intellectual disability or severe learning disorder that can interfere with their understanding of the questions or treatment materials.

Design outcomes

Primary

MeasureTime frame
Efficacy: Self-rated anxiety symptoms (Short version of the Spence Children's Anxiety Scale: Short CAS) Feasibility: Severe adverse events

Secondary

MeasureTime frame
Efficacy: 1 ) Self-rated depressive symptoms (Short-form Birleson Depression Self-Rating Scale for Children: Short-form DSRS-C) 2 ) Parent-rated anxiety symptoms in adolescents (Short CAS) 3 ) Parent-rated depressive symptoms in adolescents (Short-form DSRS-C) 4 ) Self-rated emotion regulation strategies (Emotion Regulation Questionnaire for Children and Adolescents: ERQ-CA) 5 ) Parent-rated family accommodation (Family Accommodation Scale-Anxiety: FASA) 6 ) Self-rated top problems 7 ) Parent-rated top problems 8 ) Self-rated life satisfaction (Students' Life Satisfaction Scale: SLSS) 9 ) Parent-rated adolescents' life satisfaction (SLSS) Feasibility: 1 ) Dropout proportion 2 ) Self-rated satisfaction with treatment (Client Satisfaction Questionnaire-8-Children & Youth: CSQ-8-CY) 3 ) Parent-rated satisfaction with treatment (Client Satisfaction Questionnaire-8: CSQ-8)

Contacts

Public ContactHiroko Fujisato

National Center of Neurology and Psychiatry

hi.fujisato@gmail.com+81-42-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026